Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC).

IF 0.8 Q4 ONCOLOGY
South Asian Journal of Cancer Pub Date : 2024-11-18 eCollection Date: 2025-01-01 DOI:10.1055/s-0044-1791768
Purvish M Parikh, Amish Vora, Rajan Yadav, Akhil Kapoor, Tarini Sahoo, Senthil Rajappa, Govind Babu Kanakashetty, M Vamshi Krishna, Ghanashyam Biswas, Ankur Bahl, Nikhil Ghadyalpatil, Thirumalairaj Raja, Jyoti Bajpai, Amol Akhade, Randeep Singh, Shyam Aggarwal, Maheboob Basade, S H Advani
{"title":"Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC).","authors":"Purvish M Parikh, Amish Vora, Rajan Yadav, Akhil Kapoor, Tarini Sahoo, Senthil Rajappa, Govind Babu Kanakashetty, M Vamshi Krishna, Ghanashyam Biswas, Ankur Bahl, Nikhil Ghadyalpatil, Thirumalairaj Raja, Jyoti Bajpai, Amol Akhade, Randeep Singh, Shyam Aggarwal, Maheboob Basade, S H Advani","doi":"10.1055/s-0044-1791768","DOIUrl":null,"url":null,"abstract":"<p><p>It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives).</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"45-52"},"PeriodicalIF":0.8000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925616/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1791768","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives).

Abstract Image

使用周期蛋白依赖性激酶(CDK) 4/6抑制剂治疗激素受体阳性(HR+ve)、Her2-ve早期乳腺癌(EBC)的共识指南
目前仍不可能治愈所有早期乳腺癌患者。即使他们对最初的治疗反应良好,也存在很大的复发风险,有时在几年后。随着细胞周期蛋白依赖性激酶(CDK) 4/6抑制剂的出现,辅助治疗的作用得到了改善,治愈的机会也增加了。这些共识指南将确保社区肿瘤学家能够为他们的病人做出正确的决定。专家委员会分享他们的实际经验以及一致的投票结果。有资格接受CDK4/6抑制剂辅助治疗的患者应尽早开始治疗。根据目前公布的数据,abemaciclib是CDK4/6抑制剂的首选,应用于符合条件的患者(除非有禁忌症)。为了确保最佳剂量强度和治疗计划的依从性,使用文献和患者信息材料可以提高依从性。治疗调整需要早期报告不良反应,这是患者和护理者(亲属)的责任。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
80
审稿时长
35 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信